Status:
ACTIVE_NOT_RECRUITING
LIFE - Lung Cancer, Immunotherapy, Frailty, Effect
Lead Sponsor:
University of Southern Denmark
Collaborating Sponsors:
Odense University Hospital
University of Copenhagen
Conditions:
Non-small Cell Lung Cancer
Quality of Life
Eligibility:
All Genders
18+ years
Brief Summary
The LIFE study (Lung cancer, Immunotherapy, Frailty, Effect) is investigating the unselected 'real life' non-small cell lung cancer (NSCLC) population treated with immune checkpoint inhibition.
Detailed Description
The era of immune checkpoint inhibition (ICI) has changed the treatment regimen for incurable non-small cell lung cancer. With that the hope of a more long-term survival has been introduced. ICI is gi...
Eligibility Criteria
Inclusion
- Age \> 18 years
- Stage IV NSCLC or recurrent NSCLC.
- Squamous or non-squamous histology
- Any treatment-line - Independent of prior treatment
- Candidate for checkpoint inhibitor (PD-1/PD-L1 targeting agents) immunotherapy
- No previously known allergy to PD-1/PD-L1 targeting agents.
- Able to give written consent
Exclusion
- none
Key Trial Info
Start Date :
April 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2028
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT03870464
Start Date
April 1 2018
End Date
April 1 2028
Last Update
May 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Oncology, Odense University Hospital
Odense, Denmark, 5000